Trial Profile
A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the Maximum Tolerated Dose), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With Lenalidomide in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; MT 3724 (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Molecular Templates
- 11 Jun 2021 Status changed from suspended to discontinued.
- 04 Nov 2020 According to a Molecular Templates media release, the FDA has placed MT-3724 clinical studies on partial clinical hold pending further review of a treatment-related fatality in a single subject in the Phase 2 monotherapy study.
- 04 Nov 2020 Status changed from recruiting to suspended, according to a Molecular Templates media release.